Public Health Groups Welcome Johns Hopkins University and Medicines Patent Pool Agreement for Development of Promising New TB Drug
Statement / Press • 2017Public health groups welcomed today’s announcement by Johns Hopkins University (JHU) and the Medicines Patent Pool (MPP) of an agreement that could expedite the research and development of a promising tuberculosis drug and lead to improved treatment options for people living with TB.
Petition to BRICS countries to triple funding for TB R&D
Letters • 2016Tuberculosis (TB) is the world’s deadliest infectious disease, and research into new ways to prevent, diagnose, and treat TB is urgently needed. BRICS countries—Brazil, Russia, India, China, and South Africa—are home to nearly half of all the world’s new TB cases and deaths, yet only provide 4 percent of funding for R&D to prevent them. In anticipation of the 6th Meeting of the BRICS Health Ministers, please join our call for BRICS countries to triple funding for TB research and development (R&D).
The Tuberculosis Treatment Pipeline: Activity, but No Answers
Pipeline • 2016July 15, 2016 By Erica Lessem In the past year, the development of new tuberculosis (TB) drug candidates experienced some setbacks as well as some wise pruning, with the unexpected suspension of enrollment in STAND (a phase III combination trial that includes the new drug pretomanid), the discontinuation of candidate TBA-354 (due to signs of…
Research Toward a Cure and Immune-Based and Gene Therapies
Pipeline • 2016July 15, 2016 By Richard Jefferys INTRODUCTION The pursuit of a cure for HIV infection has become a central plank of the overall research portfolio, and this has been officially underpinned by the revised HIV/AIDS priorities announced by the U.S. National Institutes of Health (NIH) in 2015.1,2 The NIH has cited the goal of developing…
2016 Hepatitis C Virus (HCV) Update
Pipeline • 2016July 15, 2016 By Mark Harrington Due to recent transitions in the TAG HCV Project [1], we did not complete a comprehensive update on hepatitis C virus (HCV) pipeline. Here are a few highlights in HCV regulation, access, and policy over the past year. Since the 2015 HCV pipeline, “New Drugs, New Strategies: Conquering Hepatitis…
Preventive Technologies: Antiretroviral and Vaccine Development
Pipeline • 2016July 15, 2016 By Tim Horn and Richard Jefferys With the continued rollout and implementation of global, national, and regional HIV incidence targets and timelines, one thing has become abundantly clear: reducing HIV rates below endemic and epidemic levels in all vulnerable populations and subpopulations everywhere in the world will require not only a monumental…
The Pediatric Antiretroviral Pipeline
Pipeline • 2016July 15, 2016 By Polly Clayden INTRODUCTION The development of new antiretroviral drugs and appropriate formulations for children continues to be far too slow. There are now 2.6 million children in need of antiretroviral treatment (ART) globally. Of those treated, more than 40% are on a suboptimal regimen.1 What is on offer to treat them…
Executive Summary
Pipeline • 2016July 15, 2016 By Mark Harrington Executive Summary – HIV THE ANTIRETROVIRAL TREATMENT PIPELINE In their chapter on Antiretroviral Treatment in this year’s Pipeline Report [9], Tim Horn and Simon Collins provide a sweeping overview of developments in the past twenty years to put those of the past year into context. The first decade after…
Toward Health Equity
TAGline • 2016We will not end HIV as an epidemic without the expertise and leadership of Black and Latino gay and bisexual men and transgender people of color. By Jeremiah Johnson In February 2016, the CDC issued a new report with a frustratingly familiar conclusion: if the current rates of new infections persist, approximately half of Black…
Decriminalization is a Public Health Strategy
TAGline • 2016We can’t end the viral hepatitis epidemics unless we end the war on drug users By Annette Gaudino “Unidentified Filipino male. Unidentified Filipino male. Unidentified Filipino female. Unidentified Filipino male…” It takes a long time to read 1,900 names, long enough to feel every inch of the concrete wall against my back. We had gathered…